HA155 | HA-155 | CAS#1229652-22-5

MedKoo Cat#: 530383 | Name: HA155

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HA155, also known as Autotaxin Inhibitor IV, is a boronic acid-based compound that inhibits autotaxin (IC50 = 5.7 nM) by selectively binding to its catalytic threonine.

Chemical Structure

HA155

CAS#1229652-22-5

Theoretical Analysis

MedKoo Cat#: 530383

Name: HA155

CAS#: 1229652-22-5

Chemical Formula: C24H19BFNO5S

Exact Mass: 463.1061

Molecular Weight: 463.29

Elemental Analysis: C, 62.22; H, 4.13; B, 2.33; F, 4.10; N, 3.02; O, 17.27; S, 6.92

Price and Availability

Size	Price	Availability
25mg	USD 350.00	2 Weeks
50mg	USD 550.00	2 Weeks
100mg	USD 950.00	2 Weeks
200mg	USD 1,450.00	2 Weeks
500mg	USD 2,450.00	2 Weeks
1g	USD 3,450.00	2 Weeks
2g	USD 5,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1312201-00-5

Synonym

HA155; HA-155; HA 155. Autotaxin Inhibitor IV.

IUPAC/Chemical Name

B-[4-[[4-[[3-[(4-fluorophenyl)methyl]-2,4-dioxo-5-thiazolidinylidene]methyl]phenoxy]methyl]phenyl]-boronic acid

InChi Key

BRWUZCBSWABPMR-XKZIYDEJSA-N

InChi Code

InChI=1S/C24H19BFNO5S/c26-20-9-3-17(4-10-20)14-27-23(28)22(33-24(27)29)13-16-5-11-21(12-6-16)32-15-18-1-7-19(8-2-18)25(30)31/h1-13,30-31H,14-15H2/b22-13-

SMILES Code

OB(C1=CC=C(COC2=CC=C(/C=C(SC(N3CC4=CC=C(F)C=C4)=O)/C3=O)C=C2)C=C1)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

(E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor.

In vitro activity:

The thrombin-mediated increase in platelet-derived LPA was completely attenuated in a dose-dependent manner by the ATX inhibitor HA155 (Fig. 1A). Reference: J Biol Chem. 2011 Oct 7;286(40):34654-63. https://pubmed.ncbi.nlm.nih.gov/21832043/

In vivo activity:

Compound 40 (HA155) was also able to decrease the plasma LPA levels upon oral administration to rats. Reference: J Med Chem. 2017 Sep 14;60(17):7371-7392. https://pubmed.ncbi.nlm.nih.gov/28731719/

	Solvent	mg/mL	mM
Solubility
	DMF	50.0	107.92
	DMSO	30.0	64.75

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 463.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Fulkerson Z, Wu T, Sunkara M, Kooi CV, Morris AJ, Smyth SS. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. J Biol Chem. 2011 Oct 7;286(40):34654-63. doi: 10.1074/jbc.M111.276725. Epub 2011 Aug 10. PMID: 21832043; PMCID: PMC3186383. 2. Joncour A, Desroy N, Housseman C, Bock X, Bienvenu N, Cherel L, Labeguere V, Peixoto C, Annoot D, Lepissier L, Heiermann J, Hengeveld WJ, Pilzak G, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Galien R, David C, Vandervoort N, Christophe T, Conrath K, Jans M, Wohlkonig A, Soror S, Steyaert J, Touitou R, Fleury D, Vercheval L, Mollat P, Triballeau N, van der Aar E, Brys R, Heckmann B. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors. J Med Chem. 2017 Sep 14;60(17):7371-7392. doi: 10.1021/acs.jmedchem.7b00647. Epub 2017 Aug 18. Erratum in: J Med Chem. 2018 May 10;61(9):4270. PMID: 28731719.

In vitro protocol:

In vivo protocol:

1. Joncour A, Desroy N, Housseman C, Bock X, Bienvenu N, Cherel L, Labeguere V, Peixoto C, Annoot D, Lepissier L, Heiermann J, Hengeveld WJ, Pilzak G, Monjardet A, Wakselman E, Roncoroni V, Le Tallec S, Galien R, David C, Vandervoort N, Christophe T, Conrath K, Jans M, Wohlkonig A, Soror S, Steyaert J, Touitou R, Fleury D, Vercheval L, Mollat P, Triballeau N, van der Aar E, Brys R, Heckmann B. Discovery, Structure-Activity Relationship, and Binding Mode of an Imidazo[1,2-a]pyridine Series of Autotaxin Inhibitors. J Med Chem. 2017 Sep 14;60(17):7371-7392. doi: 10.1021/acs.jmedchem.7b00647. Epub 2017 Aug 18. Erratum in: J Med Chem. 2018 May 10;61(9):4270. PMID: 28731719.

1: Katsamakas S, Papadopoulos AG, Hadjipavlou-Litina D. Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design. Molecules. 2016 Sep 7;21(9). pii: E1185. doi: 10.3390/molecules21091185. PubMed PMID: 27617984. 2: Albers HM, Hendrickx LJ, van Tol RJ, Hausmann J, Perrakis A, Ovaa H. Structure-based design of novel boronic acid-based inhibitors of autotaxin. J Med Chem. 2011 Jul 14;54(13):4619-26. doi: 10.1021/jm200310q. PubMed PMID: 21615078; PubMed Central PMCID: PMC3131786.